Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 14/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446167 | 0.90 | NR1H3 (0.49) | NR1H3NR1H2RXRAAR | |
| SCHEMBL2447275 | 0.90 | NR1H2 (0.42) | NR1H3NR1H2PLA2G7 | |
| SCHEMBL2446313 | 0.84 | NR1H2 (0.40) | NR1H3NR1H2 | |
| SCHEMBL2449190 | 0.84 | NR1H2 (0.49) | NR1H3NR1H2RXRA | |
| SCHEMBL3505406 | 0.84 | NR1H2 (0.60) | NR1H3NR1H2RXRA | |
| SCHEMBL3510822 | 0.81 | NR1H2 (0.60) | NR1H3NR1H2RXRA | |
| SCHEMBL3508419 | 0.81 | NR1H2 (0.57) | NR1H3NR1H2RXRA | |
| SCHEMBL2451424 | 0.80 | NR1H2 (0.49) | NR1H3NR1H2RXRA | |
| SCHEMBL2443728 | 0.79 | NR1H2 (0.49) | NR1H3NR1H2RXRA | |
| SCHEMBL3500389 | 0.79 | NR1H2 (0.40) | NR1H3NR1H2RXRAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | NR1H3 1/4885NR1H2 2/4885RXRA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.